Elevated Expression of Matrix Metalloproteinase-9 not Matrix Metalloproteinase-2 Contributes to Progression of Extracranial Arteriovenous Malformation

Ting Wei¹, Haihong Zhang¹, Neslihan Cetin², Emily Miller³, Teri Moak⁴, James Y. Suen¹,⁵ & Gresham T. Richter¹,⁵,⁶

Extracranial arteriovenous malformations (AVMs) are rare but dangerous congenital lesions arising from direct arterial-venous shunts without intervening capillaries. Progressive infiltration, expansion, and soft tissue destruction lead to bleeding, pain, debilitation and disfigurement. The pathophysiology of AVMs is not well understood. Matrix Metalloproteinases (MMPs) are thought to play an important role in pathologic processes underlying many diseases. This study investigates the expression of MMP-9 and MMP-2 in aggressive extracranial AVMs. The differential expression of MMP-9 and its regulatory factors is also examined. Herein we demonstrate that mRNA and protein expressions of MMP-9, but not MMP-2, are significantly higher in AVM tissues compared to normal tissues. The serum level of MMP-9, but not MMP-2, is also elevated in AVM patients compared to healthy controls. MMP-9/neutrophil gelatinase-associated lipocalin (NGAL) complex is also significantly increased in AVM tissues. The MMP-9/tissue inhibitor of metalloproteinases-1 (TIMP-1) complex presents as a major form detected in normal tissues. The increased and aberrant expression of MMP-9 and specific MMP-9 forms may help explain the constitutive vascular remodeling and infiltrative nature of these lesions. Specific MMP-9 inhibitors would be a promising treatment for AVMs.
angiogenesis and vascular stability, including TNF-α, TGF-β and VEGF. Two members of the MMP family, MMP-9 and MMP-2, have been specifically discovered to have a profound impact on angiogenesis and vascular remodeling in malignancies, wound healing, vascular lesions, cardiovascular diseases and inflammatory disorders. Their activities are tightly regulated by the enzyme stabilizer-neutrophil gelatinase-associated lipocalin (NGAL) and inhibitor-tissue inhibitor of metalloproteases-1 (TIMP-1).

The aim of the current study was to investigate the role of MMP-9 and MMP-2, as well as their regulatory proteins, in actively expanding extracranial AVMs. Using combined molecular technologies, we discovered that the mRNA and protein expressions of MMP-9, but not MMP-2, were abnormally elevated in human extracranial AVMs. Four MMP-9 forms were discovered in AVMs including MMP-9 monomer, MMP-9 multimer, MMP-9/NGAL complex and MMP-9/TIMP-1 complex. The first three forms showed elevated expression in AVMs compared with normal samples. MMP-9/TIMP-1 complex presented as a major form detected in normal tissues. The serum level of MMP-9, but not MMP-2, was also increased in AVM patients compared to healthy matched controls.

**Results**

**Messenger RNA expression of MMP-9, MMP-2, NGAL and TIMP-1.** Messenger RNA expression levels of MMP-9, MMP-2, NGAL and TIMP-1 are presented in Table 1 as Mean ± SD and illustrated in Fig. 1. The range of expression value and median are also presented. The individual mRNA data were presented in Table 2. The amplification amount of all target genes was normalized against that of eukaryotic 18S rRNA.

**Protein expression of MMP-9, MMP-2, NGAL and TIMP-1.** Under non-reducing conditions, blots with anti-MMP-9 antibody revealed four MMP-9 forms with molecular weights of ~250 kDa, ~150 kDa, ~125 kDa and ~92 kDa reproducibly detected in all of our AVM samples. These molecular weights corresponded with MMP-9 multimer, MMP-9/TIMP-1 complex, MMP-9/NGAL complex and MMP-9 monomer, respectively, based on the comigration positions of rhMMP-9 and purified neutrophil gelatinase-associated lipocalin (NGAL) and inhibitor-tissue inhibitor of metalloproteases-1 (TIMP-1) complex. The first three forms showed elevated expression in AVMs compared with normal samples. MMP-9/TIMP-1 complex presented as a major form detected in normal tissues. The serum level of MMP-9, but not MMP-2, was also increased in AVM patients compared to healthy matched controls.
Under reducing conditions, only the ~92 kDa MMP-9 form was detected in AVM tissues, and its expression was significantly higher than that of normal tissues using α-tubulin as a loading control (0.281 ± 0.034 vs. 0.005 ± 0.002, P = 0.03) (Fig. 2B).

Under non-reducing conditions, blots with anti-TIMP-1 antibodies illustrated two bands at ~150 kDa and ~60 kDa corresponding to MMP-9/TIMP-1 complex (MMP-9 binding with TIMP-1 dimer) and TIMP-1 dimer, respectively, in both AVM and normal tissue groups (Fig. 2C). Under reducing conditions, higher expression at ~23 kDa corresponding to NGAL was detected in AVMs, which was statistically higher than that of normal tissues using α-tubulin as a loading control (5.706 ± 1.925 vs. 0.161 ± 0.026, P = 0.038) (Fig. 2D). Blots with anti-MMP-2 antibodies revealed that no MMP-2 expression was detected in either AVMs or normal tissues (Fig. 2E).

**Gel Zymography.** In gel zymography, clear bands against dark blue background indicate the gelatinase levels including proform and active form. Four major clear bands were readily detected in all of the AVM samples, with molecular weights of ~250 kDa, ~125 kDa, ~86 kDa and ~68 kDa (Fig. 4). According to the comigration positions of rhMMP-9, rhMMP-2 and purified MMP-9/NGAL complex, the ~250 kDa and ~86 kDa bands

**Table 2. Individual data of expression levels of MMP-9 mRNA in AVMs and normal tissues.** Note: Normal tissues 9 and 10 have abnormally high level of MMP-9 mRNA, histology examination shows lymphatic malformation invasion (9) and ear dermoid cyst (10). These two data were deleted when statistical analysis was conducted.
were consistent with the MMP-9 multimer and monomer, respectively. The ~125 kDa bands corresponded to MMP-9/NGAL complex. The ~68 kDa bands represented MMP-2, which was detected in all AVM and normal samples with similar intensity reflective of normal endogenous MMP-2 expression (7.010 ± 5.582 in AVMs vs. 7.301 ± 4.272 in normal tissues, P = 0.96). This constitutive presence of MMP-2 allowed us to compare MMP-9

**Figure 3. Protein expression profile.** Comparison of protein expression levels of MMP-9 and its complexes between AVMs versus normal tissues. *significant difference; M/T, MMP-9/TIMP-1 complex; M/N, MMP-9/NGAL complex.

| Protein                  | sample  | Mean ± SD  | Min Value | Max Value | Median | P value |
|--------------------------|---------|------------|-----------|-----------|--------|---------|
| Total MMP-9              | AVM     | 0.449 ± 0.363 | 0.170     | 0.446     | 0.381  | <0.05   |
|                          | Normal  | 0.075 ± 0.052 | 0.000     | 0.161     | 0.066  |         |
| MMP-9 monomer            | AVM     | 0.194 ± 0.168 | 0.025     | 0.497     | 0.112  | <0.05   |
|                          | Normal  | 0.014 ± 0.008 | 0.000     | 0.024     | 0.013  |         |
| MMP-9/NGAL               | AVM     | 0.095 ± 0.089 | 0.031     | 0.253     | 0.050  | <0.05   |
|                          | Normal  | 0.011 ± 0.016 | 0.000     | 0.048     | 0.005  |         |
| MMP-9/TIMP-1             | AVM     | 0.114 ± 0.072 | 0.032     | 0.262     | 0.090  | <0.05   |
|                          | Normal  | 0.050 ± 0.039 | 0.000     | 0.095     | 0.046  |         |

**Table 3.** Protein expression levels of MMP-9 and its complexes in AVMs and normal tissues.

| AVM | Total MMP-9 | MMP-9 monomer | MMP-9/NGAL | MMP-9/TIMP-1 |
|-----|-------------|---------------|------------|--------------|
| 1   | 0.216       | 0.078         | 0.049      | 0.069        |
| 2   | 0.320       | 0.070         | 0.073      | 0.177        |
| 3   | 0.446       | 0.172         | 0.093      | 0.139        |
| 4   | 1.245       | 0.470         | 0.284      | 0.161        |
| 5   | 0.412       | 0.290         | 0.050      | 0.044        |
| 6   | 0.134       | 0.025         | 0.031      | 0.075        |
| 7   | 0.381       | 0.112         | 0.094      | 0.164        |
| 8   | 0.171       | 0.092         | 0.031      | 0.032        |
| 9   | 1.039       | 0.497         | 0.253      | 0.262        |
| 10  | 0.170       | 0.043         | 0.033      | 0.090        |
| 11  | 0.406       | 0.286         | 0.050      | 0.041        |

**Normal tissue**

| 1   | 0.115       | 0.021         | 0.000      | 0.095        |
| 2   | 0.084       | 0.015         | 0.000      | 0.069        |
| 3   | 0.000       | 0.000         | 0.000      | 0.000        |
| 4   | 0.161       | 0.024         | 0.048      | 0.089        |
| 5   | 0.048       | 0.012         | 0.014      | 0.023        |
| 6   | 0.042       | 0.011         | 0.012      | 0.019        |
| 7   | 0.110       | 0.020         | 0.000      | 0.090        |
| 8   | 0.039       | 0.010         | 0.010      | 0.019        |

**Table 4.** Individual data of protein levels of MMP-9 and its complexes in AVMs and normal tissues.
levels between AVMs and normal tissues and to express these levels as a ratio between MMP-9 and MMP-2 \(^1\) (Table 5, Table 6 and Fig. 5). Statistical differences were found between AVMs and normal tissues with regard to the different MMP-9 forms.

**Immunohistochemistry.** MMP-9 staining was positive in the majority of AVM samples (9/11) compared with normal tissues (0/10), and was predominantly located in perivascular cells, endothelial cells and neutrophils (Fig. 6A–C). The staining indices based on staining intensity \(\times\) staining percentage were 5.333 \(\pm\) 4.387 (0 ~ 9).

---

### Table 5. Enzyme levels of MMP-9 and its complexes in AVMs and normal tissues relative to MMP-2.

| Enzyme                  | Sample  | Mean \(\pm\) SD | Min Value | Max Value | Median | \(P\) Value |
|-------------------------|---------|-----------------|-----------|-----------|--------|-------------|
| Total MMP-9             | AVM     | 3.461 \(\pm\) 2.444 | 1.415     | 9.469     | 2.729  | \(< 0.05\) |
|                         | Normal  | 0.699 \(\pm\) 0.633 | 0.030     | 1.491     | 0.322  |             |
| MMP-9 multimer          | AVM     | 0.595 \(\pm\) 0.451 | 0.194     | 1.797     | 0.479  | \(< 0.05\) |
|                         | Normal  | 0.109 \(\pm\) 0.080 | 0.000     | 0.250     | 0.135  |             |
| MMP-9/NGAL              | AVM     | 0.876 \(\pm\) 0.631 | 0.090     | 2.334     | 0.680  | \(< 0.05\) |
|                         | Normal  | 0.135 \(\pm\) 0.153 | 0.000     | 0.423     | 0.098  |             |
| MMP-9 monomer           | AVM     | 2.030 \(\pm\) 1.408 | 0.624     | 5.338     | 1.756  | \(< 0.05\) |
|                         | Normal  | 0.429 \(\pm\) 0.411 | 0.030     | 1.021     | 0.184  |             |

Table 6. Individual data of enzyme levels of MMP-9 and its complexes in AVMs and normal tissues. *Note: normal tissue 8 has abnormally high enzyme level of MMP-9, its data were deleted when statistical analysis was conducted.

---

Figure 4. Gel zymography analysis of enzymatic levels of MMP-9 and MMP-2 in AVMs and normal tissues. RhMMP-9 (lane 1), rhMMP-2 (lane 2) and purified neutrophil MMP-9/NGAL complex (lane 3) were used as positive controls; lanes 4–5, AVMs; lanes 6–7, normal tissues.
median 9) in AVMs vs. 0.000 ± 0.000 (0 ~ 0, median 0) in normal tissues (P = 0.007). Abundant NGAL positive neutrophils were widely scattered in AVM tissues (Fig. 6D,E). MMP-2 staining was negative in all AVMs and normal tissues (Fig. 6F).

**Enzyme-linked Immunosorbent Assay.** The serum levels of MMP-9 in AVM patients were significantly higher than those of healthy normal controls (P = 0.005), whereas the serum levels of MMP-2, NGAL and MMP9/NGAL complex in AVM patients were not significantly different from those of healthy controls (P = 0.14, P = 0.37 and P = 0.68, respectively, Figs 7 and 8, Tables 7 and 8).

**Discussion**
Extracranial AVMs are thought to arise from errors in vascular morphogenesis. Histologically, they are composed of numerous aberrant arteriovenous shunts. Vascular recruitment and collateralization are thought to contribute to their progressive expansion, which makes active matrix remodeling as an important underlying mechanism. MMPs comprise a family of zinc-dependent endopeptidases involved in the matrix degradation and tissue and vascular remodeling. Two members of this family in particular, MMP-9 and MMP-2, are involved in diverse biologic processes and tightly regulated by gene expression, protein secretion, zymogen activation, and protein stabilization and inhibition. Loss of this regulation leads to a dysregulated process of matrix degradation or accumulation.
Herein we described the roles of MMP-9 and MMP-2 in the pathologic process of AVMs. We suspected involvement of these two MMPs due to the vast amount of histologically dysregulated and destabilized vascular elements and surrounding soft tissue found in AVM samples during any phase of their development or clinical presentation. To our knowledge, this is the first study to explore the relationship between MMPs and the pathophysiology of extracranial AVMs. We discovered that mRNA and protein expressions of MMP-9 are abnormally elevated in human extracranial AVMs. Similarly, circulating MMP-9 levels are elevated in AVM patients. The production of MMP-9 arises from aberrant vascular endothelial cells, perivascular cells and infiltrating neutrophils as demonstrated by the diffuse and high levels of expression seen in and also quantified by immunohistochemistry in these cell types from extracranial AVM samples compared with normal tissues. These cell sources of MMP-9...

Table 7. Serum concentrations of MMP-9, NGAL, MMP-9/NGAL and MMP-2 (ng/ml).

| Serum enzyme | Sample | Mean ± SD | Min Value | Max Value | Median | P Value |
|--------------|--------|-----------|-----------|-----------|--------|---------|
| MMP-9        | AVM    | 128.63 ± 90.80 | 3.15      | 377.77    | 123.19 | *P < 0.05* |
|              | Normal | 44.79 ± 29.73  | 0.00      | 76.24     | 55.44  |         |
| NGAL         | AVM    | 52.10 ± 19.12 | 20.74     | 91.70     | 46.51  | †P > 0.05 |
|              | Normal | 45.47 ± 12.00 | 28.34     | 62.70     | 43.77  |         |
| MMP-9/NGAL   | AVM    | 8.82 ± 9.07   | 0.00      | 30.84     | 6.26   | *P > 0.05* |
|              | Normal | 6.77 ± 13.16  | 0.00      | 43.67     | 3.44   |         |
| MMP-2        | AVM    | 279.00 ± 59.65 | 21.33     | 38.70     | 26.70  | *P > 0.05* |
|              | Normal | 250.11 ± 59.76 | 15.87     | 34.39     | 24.18  |         |
collude with the presumed pathogenesis of AVMs as a process of abnormal vascular remodeling and perivascular inflammation.

We found that neither mRNA nor protein expression of MMP-2 differed between the AVMs and normal tissues. In fact, no MMP-2 protein signal is detected by Western blot or Immunohistochemistry assays in AVMs or normal samples. Physiologic levels are detected by gel zymography without significant difference between the AVM and normal tissue groups. Thus, MMP-2 is unlikely a causative factor in the pathogenesis of AVMs.

In human tissues and biological fluids, MMP-9 can be found as a monomer, a multimer, complexes with other molecules and as a low-molecular weight truncated form. In this study, we detected all of the MMP-9 forms in our samples except the truncated form. There was some debate about the identity of the multimers. Vandooren and colleagues demonstrated the nature of the homomultimer is a reduction-sensitive trimer. The authors also demonstrated that TIMP-1 free trimer has the same efficiency to induce angiogenesis as its monomer, but is more sensitive to TIMP-1 inhibition than its monomer. This MMP9 trimer could theoretically serve as a quick TIMP-1 trap, allowing the less sensitive MMP-9 monomer to induce angiogenesis. We have conservatively elected to call this MMP-9 form a multimer in the present paper.

MMP-9 is heavily involved in tissue remodeling through the degradation of extracellular matrix substrates like collagen type IV and elastin. MMP-9 has several other functions: it can convert cytokines and chemokines into active or inactive forms; process membrane-bound and intracellular proteins like intercellular adhesion molecule-1 (ICAM-1), occludins, actin and tubulin; and release VEGF-A, a proangiogenic factor, from extracellular matrix. As a result, MMP-9 is instrumental during normal physiologic conditions, such as embryo implantation, wound healing, vascular development, and bone growth. The abnormal expression and activity of MMP-9, and/or a loss of the balance between MMP-9 and its endogenous regulators such as NGAL and TIMP-1, can disrupt normal arterial development and reorganization. Thus MMP-9 has been implicated in a host of human arterial disorders. For example, abnormalities in MMP-9 expression contribute to atherosclerotic plaque rupture and development of abdominal aortic aneurysms (AAA). AAA degeneration may be prevented by MMP inhibition or the overexpression of TIMP-1. The present study suggests that AVM expansion is also linked to high levels of MMP-9 in its monomer and multimer forms and when stabilized by the NGAL protein.

NGAL is a ~25 kDa glycoprotein that belongs to the lipocalin super-family and is predominantly expressed by neutrophils. NGAL is thought to have a crucial role in vascular remodeling and influence the activity of MMP-9 through disulfide binding to form a ~125 kDa MMP-9/NGAL complex. The MMP-9/NGAL complex is a typical product of neutrophils, which are a unique cell type that do not synthesize MMP-2 or TIMP-1, giving them a high angiogenic capacity. MMP-9/NGAL complex expression and activities have been detected in tissue and urine samples from patients with vascular anomalies and cancers. The presence of this complex has been associated with more advanced clinical stages of cancer and considered to play a key role in tumor invasion and metastasis as an independent predictor for tumor prognosis. The MMP-9/NGAL complex has also been detected in AAA tissues and thought to be related to their pathogenesis. Recent in vitro evidence indicated that NGAL greatly attenuates extracellular degradation of MMP-9 and supported the presumed protective role of NGAL for MMP-9. In this study, MMP-9/NGAL complex was detected in all of the AVM tissues with significantly higher levels when compared with normal tissues shown by Western blot and gel zymography assay, implicating that more durable MMP-9 activity via NGAL protection contributes to relentless infiltration of AVM lesions into adjacent tissue. We detected no difference between AVM patients and healthy controls when comparing circulating levels of MMP-9/NGAL complex, which implies that this specific form of MMP-9 exerts itself more locally and is linked with a disease state.

AVMs are a pathologic condition thought to be somewhat governed by inflammation and its mediators (cytokines, neutrophils, macrophages, etc), triggered by genetic/hemodynamic factors, and local hypoxia.
Histologically, abundant inflammatory cells can be found to infiltrate AVM tissue. In our study, histologic analysis showed abundant neutrophils scattered diffusely in AVM specimens (Fig. 5D). Moreover, VEGF-A is capable of inducing rapid recruitment of a subset of neutrophils from circulation which contain more MMP-9 than the ones recruited by inflammatory stimulators. Messenger RNA expression of VEGF-A in AVM tissues was significantly increased in our study compared to the normal tissues (data not shown), which contributed to greater neutrophil infiltration and TIMP-1-free MMP-9 secretion. In addition to neutrophils, some subgroups of macrophages produce TIMP-1-deficient proMMP-9. The synergy of the above factors makes them highly angiogenic.

TIMP-1 is an endogenous and specific inhibitor of MMP-9 that is able to halt the enzymatic activity of MMP-9. In most cell types, the expression of TIMP-1 is very low; latent MMP-9 usually binds to TIMP-1 before secretion except in a few specific cell types as mentioned above. Under physiologic conditions, the expression levels of MMP-9 and TIMP-1 are well balanced, which leads to normal matrix degradation and accumulation. Under pathologic conditions, this balance is disturbed with resultant excessive matrix degradation and subsequent vascular growth. AVMs are thought to be in a constitutive state of remodeling and growth despite their clinical manifestation, which may initially appear to be a state of slow expansion. Ultimately this imbalance leads to rapid growth and/ or soft tissue destruction. In the present study, all patients had actively growing AVM. Gene expression analysis by quantitative RT-PCR demonstrated significantly elevated mRNA levels of both MMP-9 and TIMP-1 in extracranial AVMs compared with normal tissue samples. Even though the mRNA level of TIMP-1 was increased in AVMs, the overexpression of MMP-9 likely was able to bypass the subsequent TIMP-1 overexpression, leading to the remodeling imbalance, excessive matrix degradation and vascular remodeling.

In this study, gel zymography showed three MMP-9 forms (MMP-9 multimer, MMP-9/NGAL complex and MMP-9 monomer) to be elevated in AVM samples compared with normal tissue samples. Because MMP-9/TIMP1 complex is dissoyed during the elution process, no clear bands were found at their expected positions. In contrast to Western blot assay, MMP-2 levels were detected in all samples with no significant difference between the AVMs and normal tissues. These findings suggest that a normal physiologic level of MMP-2 related to tissue remodeling is present under normal conditions. Because gel zymography detects inactive as well as active forms of the proteins tested, it should be noted that the results in the present study demonstrate the enzyme levels and not necessarily enzymatic activities of the MMP-9 forms and its complexes.

The weakness of this study is the small sample size secondary to the rarity of AVM cases, which is probably less than 1:100,000 individuals. However, all samples came from pathologically and radiographically confirmed, actively growing AVMs requiring intervention for control. As such, all could be grouped into a Schobinger classification III and all were removed, with or without preoperative embolization, with the same degree of manipulation and trauma. Therefore, we maintain the AVM samples can be treated as a whole. In addition, the MMP-9 serum levels were positively correlated to the tissue expression levels, with minimal standard deviation despite slightly different patient characteristics.

Since MMPs have been implicated in various pathophysiologic processes, MMP inhibitors have been extensively investigated for treatment of these conditions. Unfortunately, these inhibitors have shown little clinical efficacy because of their low selectivity. Our study was aimed at determining the specific MMP dysregulation in the pathogenesis of AVMs and providing clues to help select specific MMP inhibitors that may improve clinical efficacy and decrease side effects. Establishment of an appropriate animal model of AVM is our next step before carrying out pharmacologic trials.

In conclusion, MMP-9, and not MMP2, is significantly increased in extracranial AVMs compared with normal tissues. MMP-9/NGAL complex is a specific form of MMP-9 that protects MMP-9 enzymatic activity. The abundance of MMP-9 expression and its specific active form are most likely an important mechanism of progressive and relentless growth of AVMs. We plan to elucidate further the upstream and downstream pathways of MMP-9 to identify additional possible targets that will be focal points for our future translational work to develop a therapy for refractory AVMs.

Methods

Specimens. Fourteen extracranial AVM patients were recruited into this study after their informed consents were obtained. Among the 14 patients, 11 received surgeries. Three out of the 11 patients had preop embolization. Their lesional tissues were collected. Ten normal skins with subcutaneous tissues were obtained for normal control group. From a pathologic conditions, this balance is disturbed with resultant excessive matrix degradation and subsequent vas-

Real-time RT-PCR. 30 mg of tissue was used for RNA isolation by RNeasy Plus Kit (Qiagen). All RNA samples were then converted into cDNA by TaqMan Reverse Transcription Reagents Kit (LifeTechnologies) using random primers according to the manufacturer's instruction. The real-time PCR amplifications were performed on ABI 7900HT System (LifeTechnologies). The thermal cycling conditions were 1 cycle of 50 °C for 2 min, 1 cycle of 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. The total reaction volume of 10 μl contained 5 ng of cDNA template, 5 μl of 2 × PCR Master Mix (LifeTechnologies), and 0.5 μl of 20 × primers/probe of target genes or endogenous control assay mix. MMP-9 (Hs00234579_m1), MMP-2 (Hs01548727_m1), NGAL (Hs001008571_m1), and TIMP-1 (Hs00171558_m1) were purchased from LifeTechnologies. The Eukaryotic 18S rRNA (LifeTechnologies, Hs99999901_s1) was used as the endogenous control. The comparative Ct method was used to determine relative quantification. The amplification amount of all target genes was normalized against that of eukaryotic 18S rRNA.
Western blot analysis. Total proteins were extracted using T-PER tissue protein extraction reagent (Thermo Scientific) added with Halt Protease Inhibitor Cocktail (Thermo Scientific) and 1 mM EDTA (Invitrogen). Protein concentrations were measured using a BCA protein assay kit (Thermo Scientific). 1 ~ 30 μg of total protein was loaded on NuPAGE® Novex® 4–12% Bis-Tris Protein Gels (Invitrogen) for electrophoresis under non-reducing or reducing conditions and transferred to PVDF membranes (Bio-Rad). The membranes were blocked with 5% non-fat milk in TBST (Thermo Scientific) for 1 h at room temperature, followed by incubation with primary antibodies at 4 °C overnight. Blots were washed with TBST 3 times, followed by incubation with horseradish peroxidase conjugated secondary antibodies (Santa Cruz, 1:2000) for 1 h at room temperature. Blots were developed with Novex ECL Chemiluminescent Substrate Reagent Kit (Invitrogen) for 5 min in the dark and exposed for 2 min on Image Quant™ LAS 4000 (GE Healthcare). The primary antibodies used included mouse anti-human MMP-9 (Millipore, MAB13415, 1:200), goat anti-human MMP-9 (R&D, AF911, 1:500), mouse anti-human MMP-2 (R&D, MAB9022, 1:500), rabbit anti-human NGAL (Abcam, ab125075, 1:1000), rabbit anti-human TIMP-1 (Millipore, AB770, 1:200), rabbit anti-human GAPDH (Cell Signaling technology, 14C10, 1:1000), Recombinant human MMP-9 (R&D), MMP-2 (R&D), and purified human neutrophil MMP-9/NGAL complex (Millipore) were used as positive controls (under reducing conditions, MMP-9/NGAL complex can break down into MMP-9 and NGAL; NGAL can be used as a positive control when detecting NGAL expression in AVMs). Image results were analyzed with Image Quant TL 7.0 software (GE Healthcare).

Gel Zymography. 12 μg of total protein (same preparation as Western blot) was loaded on Novex® 10% Zymogram (Gelatin) Protein gels (Invitrogen) for electrophoresis. Gels were then renatured using Renaturing Buffer (Invitrogen) for 30 min at room temperature and equilibrated in Developing Buffer (Invitrogen) for 30 min at room temperature. After that, gels were incubated in Developing Buffer at 37 °C overnight. After a few brief rinses with distilled water, gels were stained with 0.1% Coomassie Blue (Sigma) in 40% methanol (Fisher Scientific) and 10% acetic acid (Fisher Scientific) for 1–2 h at room temperature. Tap water was used to stop destaining. Gels were pictured on Image Quant™ LAS 4000 and results were analyzed with Image Quant TL 7.0 software. Recombinant human MMP-9, MMP-2 and purified neutrophil MMP-9/NGAL complex were used as positive controls.

Immunohistochemistry. After deparaffinization and rehydration, sections were heated to 95 °C for 15 min in Citrate Buffer, pH 6.0 (Invitrogen) for antigen retrieval. 3% H2O2 (Fisher Scientific) was used to block endogenous peroxidase activity for 15 min. Sections were preincubated with 10% normal serum for 30 min at room temperature and, then incubated in primary antibodies at 4 °C overnight. Primary antibodies included rabbit anti-human MMP-9 (Cell Signaling technology, 3852, 1:200), mouse anti-human NGAL (Millipore, MABN481, 1:1000), and rabbit anti-human MMP-2 (Proteintech, 10373-2-AP, 1:50). After washing in PBST, sections were incubated in biotinylated secondary antibodies (Vector Labs, 1:200) for 30 min at room temperature followed by ABC reagent (Vector labs) for 30 min. Color was developed using ImmPACT™ DAB (Vector Labs). The sections were then counterstained with hematoxylin (Fisher Scientific), dehydrated, and mounted using permanent mounting media (Fisher Scientific). Slides with no primary antibody applied were used as the negative controls. The staining results were validated by a blind review performed by a pathologist (N.C.) with extensive experience examining vascular anomalies and Immunohistochemistry. Staining intensity was categorized into 4 levels: none (score 0), weak (score 1), moderate (score 2) and strong (score 3). Staining percentage of positive cells was categorized into 4 levels: <25% (score 0), 25–50% (score 1), 50–75% (score 2) and >75% (score 3). Staining index was calculated by multiplying staining intensity by staining percentage.

Enzyme-linked Immunosorbent Assay. Peripheral whole blood samples were obtained from venipuncture and centrifuged at 1000 × g for 15 min after 30 min of clotting at room temperature. Serum was transferred,

| Patients | Bleeding | Surgery | Preop embolization |
|----------|----------|---------|--------------------|
| 1        | No       | Yes     | No                 |
| 2        | No       | Yes     | No                 |
| 3        | Yes      | Yes     | Yes                |
| 4        | No       | Yes     | No                 |
| 5        | No       | Yes     | Yes                |
| 6        | No       | Yes     | No                 |
| 7        | Yes      | Yes     | Yes                |
| 8        | No       | Yes     | No                 |
| 9        | No       | Yes     | No                 |
| 10       | Yes      | Yes     | No                 |
| 11       | Yes      | Yes     | No                 |
| 12       | No       | No      | No                 |
| 13       | No       | No      | No                 |
| 14       | Yes      | No      | No                 |

Table 9. History of bleeding and Preop embolization of patients.
 aliquoted, and stored at –80 °C until analysis. MMP-9, MMP-2, NGAL and MMP-9/NGAL complex serum levels were determined using commercially available ELISA kits according to the manufacturer’s instructions (MMP-9, NGAL and MMP-9/NGAL complex from R&D, MMP-2 from Invitrogen). Optical density was read on an iMarkTM microplate absorbance reader (Bio-Rad).

**Statistical analysis.** The expression level was presented as the mean ± the standard deviation (SD), minimum value, maximum value and median. The significant difference between the AVM and normal tissue groups was calculated using the non-parametric Mann-Whitney U test when there was relatively wide range of expression levels among different individuals in both groups. Otherwise, the Student’s t-test was used when the data displayed normal distribution. Fisher’s exact test was used when comparing proportion differences between these two groups. The statistical analysis was run on an IBM SPSS Statistics 22. P < 0.05 was considered statistically significant.

**Study approval.** This study was approved by the Institutional Review Board of the University of Arkansas for Medical Sciences, protocol number 114012. All experiments were performed in accordance with relevant guidelines and regulations. Written informed consent was received from the participants or their guardians prior to tissue and serum collection.

**References**

1. Richter, G. T. & Suen, J. Y. Pediatric extracranial arteriovenous malformations. *Curr Opin Otolaryngol Head Neck Surg*. **19**, 455–461 (2011).
2. Liu, A. S., Mulliken, J. B., Zurakowski, D., Fishman, S. I. & Greene, A. E. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. *Plast Reconstr Surg*. **125**, 1185–1194 (2010).
3. Rietz, A. & Spiers, J. The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. *Br J Pharmacol*. **166**, 1225–1243 (2012).
4. Defour, A. et al. Small molecule anti-cancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. *Cancer Res*. **71**, 4977–4988 (2011).
5. Kumar, B. et al. P38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP2 and MMP9 activity. *Cancer Res*. **70**, 832–841 (2010).
6. Matier, J. J. et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. *Pediatrics*. **116**, 38–45 (2005).
7. Salo, T. et al. Chemically modified tetacyclines (CMT-3 and CMT-8) enable control of the pathologic remodelling of human aortic valve stenosis via MMP9 and VEGF inhibition. *Int J Cardiol*. **111**, 358–364 (2006).
8. Agrawal, S. et al. Destroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. *Exp Med*. **203**, 1007–1019 (2006).
9. Kansjorg, K., Adelheid, H. K., Dagmar, O., Abdelwahab, K. & Norbert, U. Progelatinase B forms from human neutrophils: complex formation of monomer/Lipocalin with TIMP1. *Biol Chem*. **377**, 529–533 (1996).
10. Yan, L., Borregaard, N., Kjeldsen, L. & Moses, M. A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of Gelatinase B/MMP9 and Neutrophil Gelatinase-associated Lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. *J Bio Chem*. **276**, 37258–37265 (2001).
11. Maggie, F. et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. *Thromb Haemost*. **98**, 427–433 (2007).
12. Liliana, K. et al. Expression and complex formation of MMP9, MMP2, NGAL, and TIMP1 in porcine myocardium but not in skeletal muscles in male pigs with tachycardia-induced systolic heart failure. *Biomed Res Int*. vol.2013, Article ID 283856, doi: 10.1155/2013/283856.
13. Vandooren, J., Geerts, N., Martens, E., Van Den Steen, P. E. & Oplenakker, G. Zymography methods for visualizing hydrolytic enzymes. *Nature Methods*. **3**, 211–220 (2013).
14. Christoffersson, G. et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. *Blood*. **23**, 4653–4662 (2012).
15. Kim, H. et al. Genetic consideration relevant to intracranial hemorrhage and brain arteriovenous malformations. *Acta Neurochir* **Suppl**. **105**, 199–206 (2008).
16. Vandooren, J., Van Den Steen, P. E. & Oplenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. *Crit Rev Biochem Mol Biol* **45**, 222–227 (2013).
17. Vandooren, J. et al. Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzymatic fragments differently regulated by tissue inhibitor of metalloproteinase-1. *Biochem J*. **465**, 259–270 (2013).
18. Collier, E. et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloenzyme capable of degrading basement membrane collagen. *J Biol Chem*. **263**, 6579–6587 (1998).
19. Senior, R. M. et al. Human 92- and 72-kilodalton type IV collagenases are elastases. *J Biol Chem*. **266**, 7870–7875 (1991).
20. Van Den Steen, P. E. et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4 and GRO-alpha and leaves RANTES and MCP-2 intact. *Blood*. **96**, 2673–2681 (2000).
21. Fiore, E., Fusco, C., Romero, F. & Stamenkovic, I. Matrix metalloproteinase 9 (MMP9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytoxycysis. *Oncogene*. **21**, 5213–5223 (2002).
22. Caron, A., Desrosiers, R. R. & Beliveau, R. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. *Exp Cell Res*. **310**, 105–116 (2005).
23. Cauwe, B. & Oplenakker, G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinase. *Crit Rev Rev Biol Med*. **45**, 351–423 (2010).
24. Christoffersson, G. et al. Matrix metalloproteinase-9 is essential for physiological beta cell function and islet vasularization in adult mice. *Am J Pathol*. **185**: 1094–1103 (2015).
25. Katsuki, S. et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. *Circulation*. **129**, 896–906 (2014).
26. Lijnen, H. R. Plasmin and matrix metalloproteinases in vascular remodeling. *Thromb Haemost*. **86**, 324–333 (2001).
27. Triebel, S., Blaser, I., Reiske, H. & Tschesche, H. A 25 kDa α1-microglobulin-related protein is a component of 125 kDa form of human gelatinase. *FEBS Lett*. **314**, 386–388 (1992).
28. Oplenakker, G. et al. Gelatinase B functions as regulator and effector in leukocyte biology. *J Leukoc Biol*. **69**, 851–859 (2001).
29. Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I. & Quigley, J. P. Human neutrophils uniquely release TIMP-1 free MMP-9 to provide a potent catalytic stimulator of angiogenesis. *Proc Natl Acad Sci USA*. **104**, 20262–20267 (2007).
30. Moses, M. A. et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. *Cancer Res*. **58**, 1395–1399 (1998).
31. Mohammed, M. A., Seleim, M. F., Abdalla, M. S., Sharada, H. M. & Abdel Wahab, A. H. Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. *BMC Urol.* **13**, 25–31 (2013).
32. Fernandez, C. A. *et al.* The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. *Clin Cancer Res.* **11**, 5390–5395 (2005).
33. Roy, R. *et al.* Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. *Clin Cancer Res.* **14**, 6610–6617 (2008).
34. Nuntagowat, C., Leelawat, K. & Tohtong, R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. *Clin Exp Metastasis.* **27**, 295–305 (2010).
35. Mouchtouris, N. *et al.* Biology of cerebral arteriovenous malformation with a focus on inflammation. *J Cereb Blood Flow Metab.* **35**, 167–175 (2015).
36. Zajac, E. *et al.* Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. *Blood.* **122**, 4054–4067 (2013).
37. Roderfeld, M. *et al.* Latent MMP-9 is bound to TIMP-1 before secretion. *Biol Chem.* **388**, 1227–1234 (2007).
38. Karakoc, G. B., Inal, A., Yilmaz, M., Alintas D. U. & Kindirli, S. G. Exhaled breath condensate MMP-9 levels in children with bronchiectasis. *Pediatr Pulmonol.* **44**, 1010–1016 (2009).
39. Jackson, P. L. *et al.* Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implication to cystic fibrosis proteolytic dysfunction. *Mol Med.* **16**, 159–166 (2010).

**Acknowledgements**

This study was supported, in part, by Arkansas Children’s Hospital Research Institute and the Arkansas Biosciences Institute (grant number 037047). We are grateful to Dr. Robert Clay Bunn for his helpful discussion. We thank Jessica Boswell, the clinical coordinator of Department of Otolaryngology for her time and effort devoted to our study.

**Author Contributions**

T.W. and G.T.R. conceived and designed the project. T.W., H.H.Z., E.M. and T.M. performed the experiments. T.W., G.T.R. and N.C. analyzed the data. T.W. and G.T.R. wrote the paper. J.Y.S. supervised the project. All authors contributed to the manuscript.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Wei, T. *et al.* Elevated Expression of Matrix Metalloproteinase-9 not Matrix Metalloproteinase-2 Contributes to Progression of Extracranial Arteriovenous Malformation. *Sci. Rep.* **6**, 24378; doi: 10.1038/srep24378 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.